Nanopath raises $25M Series B for 15-minute vaginal diagnostics
What's the deal? Women's health diagnostics company Nanopath has raised $25 million in a Series B to scale its rapid vaginal testing platform. Norwest Venture Partners and SV Health Investors' MedTech Convergence FundDealroom has a profile for this one. Try Dealroom → led the round, with strategic participation from the Labcorp Venture Fund, Elderberry Ventures, GingerBread CapitalDealroom has a profile for this one. Try Dealroom →, and Alumni Ventures.
What's the endgame? Nanopath has built a point-of-care platform that uses optical biosensing to detect molecular targets without nucleic acid amplification. The approach can diagnose vaginitis in about 15 minutes at the point of care, skipping the step of sending samples to an outside lab.
What's the money for? The funding will back manufacturing scale-up, team expansion, and preparations for commercialization. Nanopath plans to launch an FDA 510(k) study in 2028, targeting roughly 1,500 patients across 10 to 15 sites. Beyond vaginitis, it is exploring applications for sexually transmitted infections and urinary tract infections.
Why now? Women's-health diagnostics is drawing heavy investor interest. In September, vaginal-health company Evvy raised $40 million to expand at-home testing. Nanopath is taking a different route, aiming for results at the point of care rather than through mailed samples and lab analysis.
What could go wrong? The test remains in development and is not FDA-cleared. Commercialization and the planned expansion into UTIs and STIs depend on clearing further regulatory and clinical milestones.
"We've spent years developing and pressure-testing a fundamentally new approach to molecular diagnostics for patients who have been overlooked for far too long," said Alison Burklund, co-founder and co-chief executive officer of Nanopath.
The signal: A $25 million round signals that investors see demand for faster, in-office diagnostics in a market long served by slower lab-based testing. If Nanopath clears its 510(k) hurdle, point-of-care speed could become its edge against at-home rivals.
Read more: femtechinsider.com
Image credit: Nanopath
